Abstract
Calcific aortic stenosis is not the result of decades of wear and tear alone. Rather, it is being increasingly recognized as an inflammatory, atheromatous, and potentially modifiable disease. Exciting new research suggests that medical therapies may soon be available to retard its progression and reduce the need for surgery.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aortic Valve Stenosis* / etiology
-
Aortic Valve Stenosis* / physiopathology
-
Aortic Valve Stenosis* / prevention & control
-
Calcinosis* / etiology
-
Calcinosis* / physiopathology
-
Calcinosis* / prevention & control
-
Disease Progression
-
Homocysteine / blood
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hyperlipidemias / complications
-
Hyperlipidemias / drug therapy*
-
Risk Factors
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Homocysteine